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Background
Although surgical resection for early stage lung cancer is
the mainstay of treatment, many patients are inoperable at
the time of presentation due to either disseminated disease
or medical comorbidities (1). Novel strategies are currently
being developed to treat early-stage non-small cell lung
cancer (NSCLC) in this expanding population of highrisk and inoperable patients. Stereotactic body radiotherapy
(SBRT) modifies traditional radiation techniques to provide
a high-dose per fraction of radiation to the tumor which is
administered over a few fractions. This allows for effective
tumor ablation with preservation of the surrounding tissue
due to steep dose gradients. Radiofrequency ablation (RFA)
utilizes CT-guided placement of a radiofrequency-emitting
probe. As frictional heat energy from the probe is transferred
to the tumor, cancer cells undergo coagulation necrosis.
In an effort to expand the population of operable patients,
many groups are currently exploring the use of sublobar
resection to treat early stage tumors. Early evidence suggests
that sublobar resection may provide satisfactory oncologic
outcomes while avoiding the morbidity of standard lobectomy
in patients with poor pulmonary reserve (2). Three major
clinical trials have been developed to investigate the use of
these different modalities to treat early stage lung cancer
in inoperable or high-risk patients. A recently published
trial, RTOG 0236, is a North American phase II trial of
SBRT in patients with stage I NSCLC deemed inoperable
by a surgeon or a pulmonologist. The study showed a
local control rate of 90.6% at three years, and disease-free
survival and overall survival at three years were 48.3% and
55.8%, respectively (3). ACOSOG Z4032 is a phase III
randomized controlled trial that compared sublobar resection
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to sublobar resection with brachytherapy for the treatment
of stage I NSCLC. Thirty- and 90-day outcomes from this
study have recently been published (4). In addition, threeyear results were presented at the 2013 American Society of
Clinical Oncology (ASCO) meeting, showing a similar rate
of local recurrence for those treated with sublobar resection
(12.8%) versus sublobar resection with brachytherapy
(12.5%) (5). Overall survival was comparable between the
groups (sublobar resection =71%, sublobar resection with
brachytherapy =72%). Lastly, ACOSOG Z4033 is a phase
II prospective nonrandomized study examining high-risk
patients with stage I NSCLC treated with RFA. This study
has completed accrual, but survival and recurrence data have
not yet matured. We conducted a comparison of selection
criteria and short-term outcomes for these three studies.
Patients and setting
Patients
This study focuses on patients with stage I lung cancer that
are high risk for surgical intervention due to medical comorbidities.
Intervention(s)
We explore the selection criteria and short-term outcomes
in high risk patients treated with three different treatment
modalities: SBRT, sublobar resection, and RFA.
Objective(s)
We sought to compile data from three major North
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Table 1 Pre-treatment demographics and comorbidity profiles for RTOG 0236, ACOSOG Z4032, and ACOSOG Z4033
ACOSOG Z4032

ACOSOG Z4033

(sublobar resection)

(RFA)

55

211

51

72.5±8.8

70.2±8.5

75.6±7.5

0.00031

Age >75

21 (38.9%)

79 (37.4%)

30 (58.8%)

0.022

Female

34 (61.8%)

117 (55.5%)

28 (54.9%)

0.7

ECOG 1-2

43 (78.1%)

169 (80.1%)

42 (82.4%)

0.86

Race (white)

51 (92.7%)

199 (94.3%)

44 (86.3%)

0.023

Clinical stage IA

44 (80%)

208 (98.6%)

51 (100%)

<0.00014

Pulmonary hypertension

NR

5 (2.4%)

1 (2.0%)

0.86

Poor LV function

NR

12 (5.7%)

6 (11.8%)

0.12

MMRC dyspnea score

NR

46 (21.8%)

12 (23.5%)

0.79

pO2 ≤55 mmHg or SpO2 ≤88%

2 (3.7%)

10 (4.7%)

1 (2.0%)

0.66

pCO2 >45 mmHg

8 (14.8%)

6 (2.8%)

0

0.00025

DLCO%

61.6±30.2

46.4±15.6

43.7±18.0

0.0016

FEV1%

61.3±33.4

53.8±19.6

48.8±20.3

0.15

FVC%

79.8±23.2

74.8±17

NR

0.4

Pre-treatment characteristics

RTOG 0236 (SBRT)

N
Age (mean)

P value

Values are mean ± SD or n (%) as appropriate. P-values are from Chi-square or Kruskall-Wallis test. NR, not reported; 1, P<0.0001
Z4032 vs. Z4033; 2, P=0.04 RTOG 0236 vs. Z4033, P=0.005 Z4032 vs. Z4033; 3, P=0.04 RTOG 0236 vs. Z4032; 4, P<0.0001 RTOG
vs. Z4032, P=0.0007 RTOG 0236 vs. Z4033; 5, P=0.0004 RTOG 0236 vs. Z4032, P=0.004 RTOG 0236 vs. Z4033; 6, P=0.0008
RTOG0236 vs. Z4032, P=0.001 RTOG 0236 vs. Z4033. ECOG, Eastern Cooperative Oncology Group; DLCO%, diffusing capacity
of the lung; FEV1%, forced expiratory volume in one second.

American trials in order to compare the selection of
patients for these three treatment options, and to provide
some insight into the short-term morbidity and mortality
associated with each.
Methodology
The study was a retrospective secondary analysis of
prospectively collected data from three multicenter trials
(RTOG trial 0236, ACOSOG trial Z4032, and ACOSOG
Z4033). The data were formally requested from the RTOG
and ACOSOG, and the analysis was approved by both
organizations. We compared entry criteria and short-term
outcomes using raw data from all three trials. Categorical
data were compared using chi-square test and continuous
data using the Kruskal-Wallis test. We then performed
a propensity-matched analysis of patients treated with
SBRT and sublobar resection (RTOG 0236 and ACOSOG
Z4032). Variables including age, Eastern Cooperative
Oncology Group (ECOG) performance status, percentage
of predicted forced expiratory volume in one second
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(FEV1%), and percentage of predicted carbon monoxide
diffusing capacity of the lung (DLCO%) were used to
build a propensity score for patients with clinical stage IA
NSCLC. These scores were developed to estimate the
adjusted risks of short-term outcomes associated with the
choice of treatment (SBRT or surgery).
Primary outcomes
Main results
There were 55 patients available for analysis from RTOG
0236 (SBRT), 211 from ACOSOG Z4032 (sublobar
resection), and 51 from ACOSOG Z4033 (RFA). RFA
patients were older than those undergoing sublobar
resection or SBRT (mean age in years =75.6, 70.2, 72.5
respectively, P=0.02) (Table 1). Despite having been
identified as medically inoperable according to study
criteria, SBRT patients had superior DLCO% (61.6%)
compared with sublobar resection (46.4%) and RFA (43.7%)
(P=0.001). All patients had either T1 or T2 tumors.
Twenty percent of patients treated with SBRT had T2
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disease (n=11), compared with 1.4% of those treated with
sublobar resection (n=3). All patients treated with RFA had
T1 tumors. SBRT patients received an average of 60 Gy
of radiation. In patients undergoing surgical resection for
clinical stage IA disease, 29.3% ultimately had a higher
stage on final pathology (pIB in 25%, pIIA in 0.5%, pIIB in
1.6%, pIIIA in 1.1%, pIIIB in 0.5%, and IV in 1.1%).
Thirty- and 90-day outcomes are shown in Table 1.
For RFA, only mortality data were available. There was
no significant difference in 30-day, 90-day, or treatmentrelated mortality amongst the three modalities. There was,
however, a higher incidence of grade 3+ events at 30 days in
patients undergoing sublobar resection (28.0%) compared
with SBRT (9.1%) (P=0.004). The incidence was equivalent
at 90 days (33.2% for sublobar resection, and 21.8% for
SBRT, P=0.24). A propensity-matched score was then used
to compare SBRT (n=44) and sublobar resection (n=208)
in patients with T1 lesions. In the propensity-matched
analysis, there was no difference in 30- or 90-day grade 3+
adverse events between these two modalities. An additional
analysis was performed examining pre- and post-treatment
DLCO% and FEV1% in patients treated with SBRT
and sublobar resection. After adjusting for pre-treatment
values, there was no difference in DLCO%. However, posttreatment FEV1% was 6.4% greater in patients undergoing
sublobar resection compared with those treated with SBRT.
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Conclusions
Variability in patient populations in these three studies
underscores the need for more reliable, objective criteria to
identify the inoperable patient, the high risk but potentially
operable patient, and the very high risk patient that may
have a relatively better risk/benefit ratio from non-operative
therapy vs. operative therapy. Our propensity-matched
analysis of high-risk or inoperable patients with clinical
stage I lung cancer shows no difference in 30- or 90-day
mortality and morbidity between SBRT and sublobar
resection. These results emphasize the need for specifically
designed randomized trials to compare these treatment
modalities and further stratify patients considered high risk.
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Applicability to other populations
These trials were designed to evaluate treatment of early
stage lung cancer in high-risk or non-operable patients. The
data are not necessarily applicable to patients with more
advanced disease or to those who are satisfactory operative
candidates.
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